Dutch ingredients start-up Vivici has raised €32.5 million in Series A funding to expand its precision fermentation dairy protein business. The funding was led by APG on behalf of pension fund ABP and Invest-NL, with additional support from InnovationQuarter and existing shareholders DSM-Firmenich and Fonterra. Vivici plans to use the investment to enter new international markets, launch its second dairy protein ingredient, and build long-term manufacturing capabilities. The company’s first commercial product, Vivitein BLG, is an isolated whey protein designed to supplement dairy industry protein production, offering significant environmental benefits, including 86% lower water usage and a 68% reduction in carbon footprint. The company aims to expand its product portfolio, with the launch of lactoferrin (Vivitein LF) expected later this year. Vivici’s CEO says the funding demonstrates investors’ confidence in the company’s mission and capabilities, and paves the way for the company to turn precision fermentation into a commercial reality. The company’s product is expected to become a mainstay of consumer protein products, offering a new standard of protein with sustainability, consumer, and commercial benefits.
Vivici secures €32.5 million in its Series A funding to fuel the growth of its precision fermentation capabilities.
